Dual-acting drug increases bone formation while decreasing resorption
Romosozumab significantly reduced fracture risk, though close follow-up is required
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy